Conestoga Capital Advisors , an asset management company, released its third-quarter 2026 investor letter. The letter can be downloaded here . Conestoga Capital Advisors released its third-quarter 2026 investor letter, outlining a shifting macroeconomic backdrop for small-cap equities. After a strong start to 2026, 3Q26 headwinds—including elevated oil prices, persistent inflation, and a September Fed rate hike—drove a 9.4% quarterly drop in the Russell 2000 Growth Index (vs. +2.3% for the S&P 500). Small caps remain up 10.7% YTD, trailing large caps (+12.7%). As the market pivots toward higher-quality growth, short-term volatility should create compelling opportunities for disciplined stock selection. The Conestoga Micro Cap Composite delivered strong relative performance in 3Q, falling only -0.83% net against a -12.15% benchmark decline, bringing YTD returns to +12.50% (vs. +8.50% for the index). Outperformance was driven by robust stock selection in Health Care and Technology (where software holdings rose +16.8%), offsetting macro and execution drag in consumer-exposed positions. The strategy enters 4Q encouraged by underlying operational strength across portfolio companies. Also, check the Fund's top five holdings to see its best picks for 2026.
In its Q3 2026 investor letter, Conestoga Capital Advisors highlighted Alpha Teknova, Inc. (NASDAQ: TKNO ) as a leading contributor. Alpha Teknova, Inc. (NASDAQ:TKNO) is a biotechnology company that provides critical reagents for the discovery, development, and commercialization of novel therapies. On October 29, 2026, Alpha Teknova, Inc. (NASDAQ:TKNO) closed at $8.09 per share with a market capitalization of $499.174 million. Reflecting recent momentum, Alpha Teknova, Inc. (NASDAQ:TKNO) posted a 112.89% YTD gain, trading within a 52-week range of $1.91 to $9.48.
Conestoga Capital Advisors stated the following regarding Alpha Teknova, Inc. (NASDAQ:TKNO) in its Q3 2026 investor letter:
"Alpha Teknova, Inc.(NASDAQ:TKNO) manufactures customized reagents and other critical inputs used in life sciences research, diagnostics and biopharmaceutical development. 2Q revenue reached a company record as growth broadened across customers and end markets, while free cash outflow fell to its lowest level since before the company's 2021 IPO. Management responded to the stronger first half by substantially raising its full-year revenue outlook, with improving demand for custom products and recent investments in the commercial organization providing additional support for future growth."
Alpha Teknova, Inc. (NASDAQ:TKNO) is not on our list of the 40 Most Popular Stocks Among Hedge Funds . As per our database, 8 hedge fund portfolios held Alpha Teknova, Inc. (NASDAQ:TKNO) at the end of the second quarter, which was 11 in the previous quarter. While we acknowledge the risk and potential of Alpha Teknova, Inc. (NASDAQ:TKNO) as an investment, we believe certain AI infrastructure stocks offer far stronger long-term potential at a much more attractive entry point. If you are looking for an AI stock more promising than TKNO that operates as a critical AI tollboothand stands as the most important company in the world, check out our report about this must-own AI stock .
In its Q2 2026 investor letter, Conestoga noted that Alpha Teknova, Inc. (NASDAQ:TKNO) benefited from recovering biotech funding and customer momentum. In addition, please check out our hedge fund investor letters Q3 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years .
This article is originally published at Insider Monkey .
